Vaxart Inc (VXRT)
0.602
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 14:56
Vaxart Revenue (Quarterly): 4.933M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.933M |
| June 30, 2024 | 6.401M |
| March 31, 2024 | 2.181M |
| December 31, 2023 | 6.625M |
| September 30, 2023 | 0.446M |
| June 30, 2023 | 0.03M |
| March 31, 2023 | 0.278M |
| December 31, 2022 | 0.022M |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | 0.085M |
| December 31, 2021 | 0.074M |
| September 30, 2021 | 0.20M |
| June 30, 2021 | 0.112M |
| March 31, 2021 | 0.506M |
| December 31, 2020 | 0.356M |
| September 30, 2020 | 0.265M |
| June 30, 2020 | 0.523M |
| March 31, 2020 | 2.902M |
| December 31, 2019 | 3.916M |
| September 30, 2019 | 0.454M |
| June 30, 2019 | 0.085M |
| March 31, 2019 | 5.407M |
| December 31, 2018 | 1.767M |
| September 30, 2018 | 0.281M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.608M |
| March 31, 2018 | 1.503M |
| December 31, 2017 | 2.70M |
| September 30, 2017 | 0.10M |
| June 30, 2017 | 0.10M |
| March 31, 2017 | 4.90M |
| December 31, 2016 | 3.80M |
| September 30, 2016 | 0.10M |
| June 30, 2016 | 0.50M |
| March 31, 2016 | 5.30M |
| December 31, 2015 | 1.70M |
| September 30, 2015 | 1.70M |
| June 30, 2015 | 4.10M |
| March 31, 2015 | 5.90M |
| December 31, 2014 | 13.90M |
| September 30, 2014 | 0.70M |
| June 30, 2014 | 8.40M |
| March 31, 2014 | 29.50M |
| December 31, 2013 | 18.50M |
| September 30, 2013 | 12.30M |
| June 30, 2013 | 9.254M |
| March 31, 2013 | 12.50M |
| December 31, 2012 | 10.39M |
| September 30, 2012 | 0.632M |
| June 30, 2012 | 0.631M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.022M
Minimum
Dec 2022
6.625M
Maximum
Dec 2023
1.659M
Average
0.401M
Median
Revenue (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.035M |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 17.96M |
| Electromed Inc | 14.67M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.08M |
| Total Expenses (Quarterly) | 19.41M |
| EPS Diluted (Quarterly) | -0.06 |
| Enterprise Value | 77.62M |
| Profit Margin (Quarterly) | -285.4% |
| Earnings Yield | -68.11% |
| Normalized Earnings Yield | -68.11 |